Enhancer RNA promotes resistance to radiotherapy in bone-metastatic prostate cancer by m 6 A modification

Yu Zhao,Simeng Wen,Hang Li,Chun-Wu Pan,Yulei Wei,Ting Huang,Zhaochen Li,Yinhui Yang,Saijun Fan,Yingyi Zhang

DOI: https://doi.org/10.7150/thno.78687

IF: 11.6

2023-01-01

Theranostics

Abstract:<b>Rationale:</b> Prostate cancer metastasizes to the bone with the highest frequency and exhibits high resistance to ¹⁷⁷Lu-prostate-specific membrane antigen (PSMA) radioligand therapy. Little is known about bone metastatic prostate cancer (mPCa) resistance to radiation. <b>Methods:</b> We filtered the metastatic eRNA using RNA-seq, MeRIP-seq, RT-qPCR and bioinformation. Western blot, RT-qPCR, CLIP, co-IP and RNA pull-down assays were used for RNA/protein interaction, RNA or protein expression examination. MTS assay was used to determine cell viability in vitro, xenograft assay was used to examine the tumor growth in mice. <b>Results:</b> In this study, we screened and identified bone-specific N6 adenosine methylation (m⁶A) on enhancer RNA (eRNA) that played a post-transcriptional functional role in bone mPCa and was correlated with radiotherapy (RT) resistance. Further data demonstrated that RNA-binding protein KHSRP recognized both m⁶A at eRNA and m⁶Am at 5'-UTR of mRNA to block RNA degradation from exoribonuclease XRN2. Depletion of the <i>MLXIPe</i>/KHSRP/<i>PSMD9</i> regulatory complex inhibited tumor growth and RT sensitization of bone mPCa xenograft <i>in vitro</i> and <i>in vivo</i>. <b>Conclusions:</b> Our findings indicate that a bone-specific m⁶A-modified eRNA plays a vital role in regulating mPCa progression and RT resistance and might be a novel specific predictor for cancer RT.

medicine, research & experimental